

**DUO-COTECXIN BY BEIJING HOLLEY-COTEC
PHARMACEUTICALS CO., LTD.**



Beijing Holley-Cotec Pharmaceuticals Co., Ltd. (Holley-Cotec) is part of the Holleypharm Group featured by a full range of the value chain of products based on artemisinin and its derivatives. Based in Beijing, Holley-cotec is dedicated to developing and promoting pharmaceutical products in international markets.

Holley-Cotec launched COTECXIN, an innovative artemisinin-based anti-malarial with DHA as ingredient, to African markets back in 1993. Since then, Holley-Cotec has been standing with all people fighting malaria in endemic regions in Africa, South-East Asia and Pan America. COTECXIN was originally developed in China and is one of the few drugs for which China owns the intellectual property right. In 2005, DUO-COTECXIN, the fixed-dose Artemisinin-based Combination Therapy (ACT) was registered in Kenya. Manufactured according to WHO GMP standards and supported by clinical data collected from multi-center studies, the product launch was a success in line with WHO ACT policy. Its features and benefits including high efficacy, excellent safety and tolerability, simple dosage and the advantage of post-treatment prophylactic effect for 28 days, have been acknowledged by the professionals who are fighting malaria in the field. Now DUO-COTECXIN is in the Essential Medicine List in 8 countries in the world.

Not only Holley-Cotec has its local marketing teams and subsidiaries in major endemic countries, but also it has strong links with local agents in numerous countries. Along with the good reputation of COTECXIN and DUO-COTECXIN, Holley-Cotec is reinforcing its position in the African and Asian markets and enhancing its international company image.